AZN vs NRXS

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

NRXS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen a speculative 217% price increase over the last year, this is completely disconnected from its fundamentals, as evidenced by a -218.55% profit margin and an extreme Price-to-Book ratio of 23.35. Despite moderate revenue growth and a strong current ratio, the company is destroying equity at an alarming rate (ROE -285.36%). The current valuation is unsustainable without a massive and immediate pivot to profitability.